| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 170.1 | 175.9 | 138.0 |
| Other income | 2.0 | 1.0 | 1.5 |
| Total income | 172.1 | 176.9 | 139.6 |
| Profit before exceptional items & tax | 7.8 | 16.4 | 15.3 |
| Profit before tax | 7.8 | 16.4 | 15.3 |
| Net profit | 6.6 | 12.2 | 11.6 |
| Operating margin | 4.5% | 9.3% | 11.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -43.10% |
|---|---|
| Net profit, quarter on quarter | -45.90% |
| Revenue, year on year | +23.30% |
NSE results filing, NSE: CGRAPHICS. Figures extracted from the filing.
Creative Graphics Solutions India Ltd: key numbers
- Share price
- ₹134.05
- Market cap
- ₹325.6 Cr
- Revenue (annual)
- ₹346.0 Cr
- Net profit (annual)
- ₹18.76 Cr
- P/E (TTM)
- 17.4×Sector 41.4×
- Promoter holding
- 68.07%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Creative Graphics Solutions India Ltd
All →Creative Graphics Solutions India Annual General Meeting
Creative Graphics Solutions India Limited conducted its 12th Annual General Meeting on September 25, 2026. Members considered and approved the financial statements and director-related resolutions.
Creative Graphics Solutions India Annual Report
Creative Graphics Solutions India Limited issued a corrigendum for its FY 2025-26 Annual Report. The update rectifies a clerical omission of the "SPECIAL BUSINESS" heading.
Creative Graphics Solutions India Earnings Call: Key Takeaways
Management discusses FY26 performance with consolidated revenue of ₹348cr (up from ₹135cr). Focus remains on aggressive capacity expansion in pharma packaging and export growth.
Creative Graphics Solutions India Earnings Call: Key Takeaways
Creative Graphics is pivoting from flexographic plates to high-volume pharmaceutical packaging, targeting aggressive expansion but facing significant margin pressure from rising aluminum costs.